Boardroom Alpha
Boardroom Alpha
PARA · Amended Current Report (Form 8-K/A) · Filed September 24, 2026

Banzai International Inc — Amended Current Report (Form 8-K/A)

Form
8-K/A
Filed
September 24, 2026
Period
Sep 11, 2026
Ticker
PARA
Accession
0001493152-26-044168
Boardroom Alpha · Filing insights

Banzai amended its private placement with Evergreen Capital; Purchaser gains 25% participation rights and revised tranche structure and cross-default threshold.

About Banzai International Inc
Market cap
$2M
1Y TSR
−98.2%
3Y TSR
−97.9%
Board grade
D
Sector
Technology
CEO
Joseph P Davy
Last annual meeting: Oct 16, 2026 · View full Banzai International Inc profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): September 24, 2026 (September 11, 2026)

 

Banzai International, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39826   85-3118980

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

435 Ericksen Ave, Suite 250

Bainbridge Island, Washington

  98110
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (206) 414-1777

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A common stock, par value $0.0001 per share   PARA   The Nasdaq Capital Market
         
Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $115,000.00   PARAW   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Explanatory Note

 

The registrant is filing this amendment to disclose revised terms to a previous filed agreement.

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On September 11, 2026, Banzai International, Inc. (the “Company”) filed the initial Current Report on Form 8-K (the “Initial 8-K”) to disclose that it entered into that certain Securities Purchase Agreement (the “Purchase Agreement”) with an accredited investor (the “Purchaser”), dated as of September 4, 2026. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchaser, in a private placement (the “Private Placement”), (i) a convertible promissory note (the “Note”) in an initial principal amount of $2,142,857.14, subject to increase up to $3,571,428.57 in aggregate principal amount, and (ii) a warrant (the “Common Warrant”) to purchase up to 779,221 shares of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), with additional Common Warrants to purchase up to 519,480 additional shares of Common Stock issuable in connection with subsequent tranche fundings. The Private Placement was made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 promulgated thereunder. Aegis Capital Corp. (“Aegis” or the “Placement Agent”) acted as the exclusive placement agent for the Private Placement.

 

Since the Initial 8-K, the Company and Purchaser have revised some of the terms of the Purchase Agreement and related instruments. Most notably, the revised terms dictate that the threshold amount for cross defaults under the Purchase Agreement shall be set at $250,000. Additionally, the Purchaser now has a 25% participation right in the Company’s future financings, with some noted exceptions, until the later of September 18, 2027 and the date that Aegis ceases to act as the Company’s investment bank. The parties also agreed to revise the $500,000 Tranche 2 funding into two separate fundings of $190,000 and $310,000, rather than one lump sum payment.

 

The foregoing description of the revised terms of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Letter Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
4.1   Convertible Promissory Note, dated September 4, 2026, issued by Banzai International, Inc. to Evergreen Capital Management LLC. (incorporated by reference to the Current Report on Form 8-K filed on September 11, 2026)
4.2   Common Stock Purchase Warrant, dated September 4, 2026, issued by Banzai International, Inc. to Evergreen Capital Management LLC. (incorporated by reference to the Current Report on Form 8-K filed on September 11, 2026)
10.1   Securities Purchase Agreement, dated September 4, 2026, by and between Banzai International, Inc. and Evergreen Capital Management LLC. (incorporated by reference to the Current Report on Form 8-K filed on September 11, 2026)
10.2   Form of Lock-Up Agreement. (incorporated by reference to the Current Report on Form 8-K filed on September 11, 2026)
10.3   Letter Agreement dated September 18, 2026 between the Company and Evergreen Capital Management LLC
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: September 24, 2026

 

  BANZAI INTERNATIONAL, INC.
     
  By: /s/ Joseph Davy
    Joseph Davy
    Chief Executive Officer

 

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Banzai International Inc (PARA)

Reference

Frequently asked questions

When did Banzai International Inc file this 8-K/A?
Banzai International Inc (PARA) filed this Amended Current Report (Form 8-K/A) with the SEC on September 24, 2026. The accession number assigned by EDGAR is 0001493152-26-044168.
What does an 8-K/A disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Banzai amended its private placement with Evergreen Capital; Purchaser gains 25% participation rights and revised tranche structure and cross-default threshold. This is Boardroom Alpha's one-line summary of the amended current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Banzai International Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K/A Banzai International Inc has filed under CIK 1826011, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer